Linked Life Data

21121772

Source:http://linkedlifedata.com/resource/pubmed/id/21121772

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-12-2
pubmed:abstractText
Sulfonylureas are mainly metabolized by the enzyme CYP2C9. Two allelic variants, CYP2C9*2 and CYP2C9*3, result in decreased metabolic capacity and have been associated with elevated sulfonylurea serum levels. However, most of the available data originates from pharmacokinetic analyses performed in healthy individuals. In this study, the effect of CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable dose of sulfonylureas was investigated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1744-8042
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1517-23
pubmed:meshHeading
pubmed-meshheading:21121772-Alleles, pubmed-meshheading:21121772-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:21121772-Blood Glucose, pubmed-meshheading:21121772-Diabetes Mellitus, Type 2, pubmed-meshheading:21121772-Dose-Response Relationship, Drug, pubmed-meshheading:21121772-Drug Prescriptions, pubmed-meshheading:21121772-Female, pubmed-meshheading:21121772-Genetic Testing, pubmed-meshheading:21121772-Genotype, pubmed-meshheading:21121772-Humans, pubmed-meshheading:21121772-Hypoglycemic Agents, pubmed-meshheading:21121772-Kaplan-Meier Estimate, pubmed-meshheading:21121772-Male, pubmed-meshheading:21121772-Medical Records, pubmed-meshheading:21121772-Middle Aged, pubmed-meshheading:21121772-Netherlands, pubmed-meshheading:21121772-Polymorphism, Genetic, pubmed-meshheading:21121772-Primary Health Care, pubmed-meshheading:21121772-Retrospective Studies, pubmed-meshheading:21121772-Saliva, pubmed-meshheading:21121772-Sulfonylurea Compounds, pubmed-meshheading:21121772-Time Factors
pubmed:year
2010
pubmed:articleTitle
Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
pubmed:affiliation
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
pubmed:publicationType
Journal Article